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Accepted 11 September 2012Obstetricians may unexpectedly encounter placenta accreta
in the third stage of labor during vaginal delivery. An inad-
vertent attempt to remove a retained placenta due to accreta at
delivery may lead to uterine inversion or devastating post-
partum hemorrhage (PPH) [1]. The risk factors of placenta
accreta include but are not limited to previous uterine surgery
and prior endometrial injuries secondary to inflammation,
curettage or electric cauterization [2]. It remains a great
challenge for obstetricians to suspect and identify placenta
accreta occurring in a primigravida who has a lack of risk
factors.
A 29-year-old primigravid woman suffered from a retained
placenta, which was trapped in the cervix for 50 minutes after
vaginal delivery. The patient had no previous histories of
uterine surgery or infection. The signs of expulsion and
elongation of the umbilical cord were noticed and the front
part of placenta was palpable at the cervical os and visible
from the vagina. A transabdominal sonography performed 1
hour after vaginal delivery revealed a very thin posterior
uterine wall at the placental implantation site and an active
low-resistance intraplacental flow, indicating an active func-
tional placenta accreta with incomplete separation. Trans-
catheter arterial embolization (TAE) of the bilateral uterine
arteries using gelfoam, which was performed 3 hours after
delivery, prevented acute intrauterine bleeding. Three days
after the application of TAE, significant amounts of blood
accumulated in the uterine cavity proximal to the placenta that
was confined to the excessively distended lower segment of
the uterus (Fig. 1A). An obscured interface between the pla-
centa and the very thin posterior uterine wall was clearly
shown on computed tomography scan (Fig. 1B). Without
anesthesia, ring forceps were used to remove most of the
placenta except for the residual part of placenta accreta, which* Corresponding author. Department of Obstetrics and Gynecology, Kaoh-
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http://dx.doi.org/10.1016/j.tjog.2012.09.036is firmly attached to the uterine wall. During the procedure,
roughly 600 mL of blood was successfully drained from the
uterus. To reduce and prevent further PPH, 1 mg of recom-
binant activated factor VII (Novoseven RT, Novo Nordisk,
Denmark) was intravenously administered and oral miso-
prostol (0.2 mg, daily) and tranexamic acid (250 mg, 3 times
a day) were prescribed. No blood transfusion was adminis-
tered because the vital signs of the patient remained stable and
her hemoglobin level was 100 g/L. Seven days later, despite no
obvious vaginal bleeding, transvaginal sonography revealed
a 5 cm  4 cm  3 cm blood clot in the uterine cavity and
a 4 cm  4 cm  3 cm residual placenta that was adhered to
the thin posterior uterine wall (Fig. 2A) and associated with
significantly less vascularity compared to previous ultrasound
appearance. The placenta and the blood clots were removed
piece by piece using a ring forceps under ultrasound guidance.
The entire procedure caused minimal uterine bleeding. The
follow-up sonography was ordinary except that there was
a thin wall in the posterior lower segment of the uterus
(Fig. 2B). The serum level of b-human chorionic gonadotropin
returned to normal within 1 month postpartum and the patient
felt well.
Placental separation from the uterine wall is usually
accompanied by signs of expulsion and elongation of the
umbilical cord outside the vagina followed by descent of the
placental tissue that is palpable at the cervical os. Of note,
these signs may appear when partial placental separation
occurs as a result of focal placenta accreta, leading to
a descending placenta trapped in the cervix concomitant with
PPH accumulating in the uterine cavity. Color Doppler images
of postvaginal delivery placenta accreta performed during the
third stage of labor are scant in the literature. It is prudent to
use color Doppler studies to exclude the presence of placenta
accreta prior to an attempt to remove a retained placenta
during vaginal delivery [3]. Conservative treatment of placenta
accreta is feasible but carries the risk of adverse events, such
as infection, pain, coagulopathy, and PPH [4]. TAE using
gelfoam plays a role in minimizing acute PPH and acceleratescs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
Fig. 2. (A) Transvaginal sonography performed 10 days after vaginal delivery
displayed blood clots and residual placental tissues (PL), which were adhered
to the thin posterior uterine wall (arrow) and associated with significantly less
vascularity compared to previous ultrasound appearance. The blood clots and
the residual placenta were removed by the use of a ring forceps under ultra-
sound guidance. (B) The follow-up transvaginal sonography was ordinary
except that there was a thin wall in the posterior lower segment of the uterus
(arrow).
Fig. 1. (A) Sagittal computed tomography showing a distended uterus filled
with a large quantity of blood, a retained placenta (PL) trapped in the lower
segment of the uterus, and an obscured interface between the placenta and the
very thin posterior uterine wall (arrow). (B) Axial view showing an obscured
interface (arrows) between the placenta and the very thin posterior uterine
wall, corresponding to placenta accreta. Most of the placenta was removed by
the use of ring forceps.
138 F.-N. Cho et al. / Taiwanese Journal of Obstetrics & Gynecology 52 (2013) 137e139the involution of placenta accreta [3,5], but may fail to prevent
delayed PPH because of recanalization of blood vessels after
absorption of gelfoam. Of note, renal failure due to the use of
over-dose contrast, necrosis of the bladder or uterus, pulmo-
nary embolism, and embolization of leg vessels are the po-
tential major complications after the application of TAE [4].The recommended dose of recombinant activated factor VII
to treat acute PPH is 0.04e0.09 mg/kg [6]. A small dose
(1.2 mg) of recombinant activated factor VII has been reported
to successfully deal with PPH due to immune thrombocyto-
penia purpura [7]. Thus a small dose of recombinant activated
factor VII may be considered to reduce and prevent delayed
uterine bleeding due to a residual placenta. However, blood
clots may gradually accumulate in the uterine cavity and need
further management by the use of ring forceps or oral miso-
prostol [7].
Ring forceps provide the benefit of allowing one to firmly
clamp, gently twist and remove the residual placenta with less
bleeding and complication. Under ultrasound guidance, the
application of ring forceps is simple and seems to be safe.
This alternative approach enables the patient to retain her
uterus and avoids invasive major surgery. The risk of recur-
rence of placenta accreta during future delivery still exists,
however, and obstetricians should deliver this message to the
patient [8].
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placenta accreta by color Doppler studies obviated an attempt
to remove the retained placenta and prevented devastating
acute PPH. In combination with the application of emboliza-
tion of uterine arteries and recombinant factor VII, the use of
ring forceps under ultrasound guidance seems to be another
alternative method to efficiently tackle postvaginal delivery
placenta accreta and preserve the uterus for future fertility.References
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